Mera Pharmaceuticals Stock Net Income
| MRPI Stock | USD 0.0001 0.00 0.00% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Mera Pharmaceuticals' long-term financial health and intrinsic value.
Mera |
Mera Pharmaceuticals Company Net Income Analysis
Mera Pharmaceuticals' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Mera Pharmaceuticals Net Income | (5.58 K) |
Most of Mera Pharmaceuticals' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mera Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Mera Pharmaceuticals reported net income of (5,580). This is 100.0% lower than that of the Biotechnology sector and 100.01% lower than that of the Health Care industry. The net income for all United States stocks is 100.0% higher than that of the company.
Mera Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mera Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Mera Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Mera Pharmaceuticals by comparing valuation metrics of similar companies.Mera Pharmaceuticals is currently under evaluation in net income category among its peers.
Mera Fundamentals
| Return On Asset | -1.74 | |||
| Current Valuation | 167.19 K | |||
| Shares Outstanding | 557.3 M | |||
| Price To Sales | 3.62 X | |||
| Revenue | 302.62 K | |||
| Gross Profit | 286.36 K | |||
| EBITDA | (192.75 K) | |||
| Net Income | (5.58 K) | |||
| Cash And Equivalents | 4.32 K | |||
| Total Debt | 299.14 K | |||
| Current Ratio | 0.06 X | |||
| Cash Flow From Operations | (71.84 K) | |||
| Beta | 3.16 | |||
| Market Capitalization | 222.92 K | |||
| Total Asset | 71 K | |||
| Retained Earnings | (8.89 M) | |||
| Working Capital | (881 K) | |||
| Current Asset | 54 K | |||
| Current Liabilities | 935 K |
About Mera Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mera Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mera Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mera Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Mera Pink Sheet
Mera Pharmaceuticals financial ratios help investors to determine whether Mera Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Mera with respect to the benefits of owning Mera Pharmaceuticals security.